Erlotinib vs Lazertinib

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Non-Small Cell Lung Cancer

Shared mechanism: EGFR · full Non-Small Cell Lung Cancer pipeline

Erlotinib

Rights held by Cheplapharm Arzneimittel GmbH and partners

Approved in Non-Small Cell Lung Cancersmall molecule
Partial signal

NCT00446225 · Phase 3 · completed

EURTAC was a randomized, open-label Phase 3 in 174 patients with EGFR-mutant advanced NSCLC comparing erlotinib with platinum-based chemotherapy. Its primary endpoint, progression-free survival, is a clinical outcome and was met (HR 0.42). An open-label trial is never graded strong under the rubric.

Next expected readout: December 2027 · NCT04449874 (registry estimate)

Reported efficacy

Progression Free-survival (From the date of randomization to the date of last follow up, assessed up to 24 months): Primary endpoint, progression-free survival: hazard ratio 0.42 (95% CI 0.27 to 0.64), p=0.0001, erlotinib vs platinum doublet chemotherapy in EGFR-mutant NSCLC (CT.gov posted results). (met)

Result source: NCT00446225

Lazertinib

Marketed by Johnson & Johnson and partners

Approved in Non-Small Cell Lung Cancersmall molecule
Partial signal

NCT04248829 · Phase 3 · completed

The trial randomized 393 participants to lazertinib or an active gefitinib control with double-blind treatment. Its primary clinical endpoint, investigator-assessed progression-free survival, was met: median 20.6 vs 9.7 months (HR 0.45, 95% CI 0.34 to 0.58; P < .001; PMID 37379502).

Next expected readout: December 2026 · NCT05463224 (registry estimate)

Reported efficacy

Progression-Free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as Assessed by Blinded Independent Central Review (BICR) (From randomization to either disease progression or death whichever occurs first (up to 32.8 months)): Progression-Free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as Assessed by Blinded Independent Central Review (BICR) (From randomization to either disease progression or death whichever occurs first (up to 32.8 months)): Experimental: Arm A (Open-label): Amivantamab + Lazertinib 23.72 Months (95% CI 19.12 to 27.66) | Experimental: Arm C (Double-blind): Lazertinib+Placebo Matching Osimertinib 18.46 Months (95% CI 14.75 to 20.11) vs Active Comparator: Arm B (Double-blind): Osimertinib+Placebo Matching Lazertinib 16.59 Months (95% CI 14.78 to 18.46) (met)

Result source: NCT04487080

Results for Non-Small Cell Lung Cancer

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointErlotinibLazertinib
PFS, median7.6 vs 6+1.6 vs placebon 226NCT00883779
7 other results
20.6 vs 9.7vs Gefitnib240 mg · n 196NCT04248829
6 other results
OS, median11.9 vs 10.2vs Standard of Caren 245NCT01351415
11 other results
9.1b240 mg · n 11NCT04075396
1 other result
  • 7.7 320 mg · n 9 · Phase 1/2 · secondary NCT04075396
ORR42.9% vs 17.8%+25.1 vs placebon 226NCT00883779
23 other results
76% vs 76.1%vs Gefitnib240 mg · n 196NCT04248829
2 other results
  • 26.7% 240 mg · n 15 · Phase 1/2 · secondary NCT04075396
  • 7.7% 320 mg · n 13 · Phase 1/2 · secondary NCT04075396
Duration of response, median10.3 vs 5.6+4.7 vs placebon 97NCT00883779
3 other results
19.4 vs 8.3vs Gefitnib240 mg · n 196NCT04248829
1 other result
  • 2.8 320 mg · n 1 · Phase 1/2 · secondary NCT04075396

PFS, median

Erlotinib
7.6 vs 6+1.6 vs placebon 226NCT00883779
7 other results
Lazertinib
20.6 vs 9.7vs Gefitnib240 mg · n 196NCT04248829
6 other results

OS, median

Erlotinib
11.9 vs 10.2vs Standard of Caren 245NCT01351415
11 other results
Lazertinib
9.1b240 mg · n 11NCT04075396
1 other result
  • 7.7 320 mg · n 9 · Phase 1/2 · secondary NCT04075396

ORR

Erlotinib
42.9% vs 17.8%+25.1 vs placebon 226NCT00883779
23 other results
Lazertinib
76% vs 76.1%vs Gefitnib240 mg · n 196NCT04248829
2 other results
  • 26.7% 240 mg · n 15 · Phase 1/2 · secondary NCT04075396
  • 7.7% 320 mg · n 13 · Phase 1/2 · secondary NCT04075396

Duration of response, median

Erlotinib
10.3 vs 5.6+4.7 vs placebon 97NCT00883779
3 other results
Lazertinib
19.4 vs 8.3vs Gefitnib240 mg · n 196NCT04248829
1 other result
  • 2.8 320 mg · n 1 · Phase 1/2 · secondary NCT04075396
  1. b Single-arm result: the trial had no control arm, so the number has no comparator and does not compare with a randomised result.
  2. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  3. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
5 other shared endpoints and safety

Coverage. Erlotinib: 9 of 9 rows · Lazertinib: 9 of 9 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricErlotinib
Rows use multiple source trials
Lazertinib
Rows use multiple source trials
Disease Control
responder rate · % of participants
80.2% (n=245) vs 77% (n=240) Standard of Carea,b,c
NCT01351415 · Phase 3 · registry result, not featured evidence · combination
4 other source trials
67.3% (n=226) vs 64.4% (n=225) placebo
NCT00883779 · Phase 3 · registry result, not featured evidence
64.5% (n=76) vs 53.8% (n=78) placebo @ 16wk
NCT01998919 · Phase 2 · registry result, not featured evidence · combination
73% (n=63) vs 85.2% (n=61) Bevacizumab + Chemotherapy
NCT00531960 · Phase 2 · registry result, not featured evidence · combination
85.7% (n=7) vs 50% (n=8) Gemcitabine
NCT00518011 · Phase 2 · registry result, not featured evidence · combination
93.9% (n=196) vs 93.9% (n=197) Gefitnib240 mga,b,c
NCT04248829 · Phase 3 · Non-Small Cell Lung Cancer · phase 3
Duration of Response
time to event · months
No placebo or comparator arm
3.76 months*d,a,b,c
NCT00518011 · Phase 2 · registry result, not featured evidence · combination · converted to months from 16.3 weeks as posted
NA months240 mge,d,a,b,c
NCT04075396 · Phase 1/2 · registry result, not featured evidence
show 1 more dose
2.8 months320 mg
NCT04075396 · Phase 1/2 · registry result, not featured evidence
ORR
responder rate · % of participants
No placebo or comparator arm
12.5% (n=24)e,d,a,b,c
NCT00800202 · Phase 2 · registry result, not featured evidence · combination
show 1 more dose
62.7% (n=67)
NCT00800202 · Phase 2 · registry result, not featured evidence · combination
26.7% (n=15)240 mge,d,a,b,c
NCT04075396 · Phase 1/2 · registry result, not featured evidence
show 1 more dose
7.7% (n=13)320 mg
NCT04075396 · Phase 1/2 · registry result, not featured evidence
Overall Survival
time to event · months
No placebo or comparator arm
6.08 monthse,d,a,c
NCT00550537 · Phase 2 · registry result, not featured evidence
show 2 more doses
12.53 months
NCT00550537 · Phase 2 · registry result, not featured evidence · combination
17.23 months
NCT00550537 · Phase 2 · registry result, not featured evidence · combination
9.1 months240 mge,d,a,c
NCT04075396 · Phase 1/2 · registry result, not featured evidence
show 1 more dose
7.7 months320 mg
NCT04075396 · Phase 1/2 · registry result, not featured evidence
PFS
time to event · months
No placebo or comparator arm
6.3 monthse,d,a,b,c
NCT00800202 · Phase 2 · registry result, not featured evidence · combination
show 1 more dose
6.7 months
NCT00800202 · Phase 2 · registry result, not featured evidence · combination
3.1 months240 mge,d,a,b,c
NCT04075396 · Phase 1/2 · registry result, not featured evidence
show 1 more dose
4.2 months320 mg
NCT04075396 · Phase 1/2 · registry result, not featured evidence
Dropout rate
n/a: no completion milestonef
NCT01351415 · Phase 3 · registry result, not featured evidence · combination
show 42 more results
38.1%
NCT00883779 · Phase 3 · registry result, not featured evidence
—
NCT00257608 · Phase 3 · registry result, not featured evidence · combination
5.5%
NCT00621049 · Phase 2 · registry result, not featured evidence
n/a: no completion milestoneBevacizumab+Erlotinib
NCT00800202 · Phase 2 · registry result, not featured evidence · combination
n/a: no completion milestoneBevacizumab+Paclitaxel+Carboplatin
NCT00800202 · Phase 2 · registry result, not featured evidence · combination
47.3%
NCT01998919 · Phase 2 · registry result, not featured evidence · combination
78.9%
NCT00701558 · Phase 2 · registry result, not featured evidence · combination
n/a: no completion milestone
NCT00531960 · Phase 2 · registry result, not featured evidence · combination
n/a: no completion milestone
NCT00518011 · Phase 2 · registry result, not featured evidence · combination
—200 mg
NCT02039674 · Phase 1/2 · registry result, not featured evidence · monotherapy
n/a: no completion milestonePart 2 Cohort G+ (Pembro 200 mg+Pe
NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination
n/a: no completion milestonePart 1 Cohort B10 (Pembro 10 mg/kg
NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination
n/a: no completion milestonePart 1 Cohort C10 (Pembro 10 mg/kg
NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination
n/a: no completion milestonePart 1 Cohort D1 (Pembro 10 mg/kg+
NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination
n/a: no completion milestonePart 1 Cohort D2 (Pembro 10 mg/kg+
NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination
—Part 1 Cohort A2 (Pembro 2 mg/kg+P
NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination
n/a: no completion milestonePart 1 Cohort B2 (Pembro 2mg/kg+Pa
NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination
n/a: no completion milestonePart 1 Cohort C2 (Pembro 2 mg/kg+P
NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination
n/a: no completion milestonePart 1 Cohort D4 (Pembro 2 mg/kg+I
NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination
n/a: no completion milestonePart 1 Cohort E (Pembro 2 mg/kg+Er
NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination
n/a: no completion milestonePart 1 Cohort F (Pembro 2 mg/kg+Ge
NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination
n/a: no completion milestonePart 2 Cohort H (Pembro 2mg/kg+I)
NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination
—Part 1 Cohort A10 (Pembro10mg/kg+P
NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination
0%Arm A: Nivolumab + Gemcitabine + C
NCT01454102 · Phase 1 · registry result, not featured evidence · combination
0%Arm B: Nivolumab + Pemetrexed + Ci
NCT01454102 · Phase 1 · registry result, not featured evidence · combination
0%Arm C10: Nivolumab + Paclitaxel +
NCT01454102 · Phase 1 · registry result, not featured evidence · combination
7.1%Arm C5: Nivolumab + Paclitaxel + C
NCT01454102 · Phase 1 · registry result, not featured evidence · combination
—Arm C: Nivolumab + Paclitaxel + Ca
NCT01454102 · Phase 1 · registry result, not featured evidence · combination
0%Arm D: Nivolumab + Bevacizumab Mai
NCT01454102 · Phase 1 · registry result, not featured evidence · combination
14.3%Arm E: Nivolumab + Erlotinib
NCT01454102 · Phase 1 · registry result, not featured evidence · combination
5.8%Arm F: Nivolumab
NCT01454102 · Phase 1 · registry result, not featured evidence
—Arm G: Nivolumab + Ipilimumab
NCT01454102 · Phase 1 · registry result, not featured evidence · combination
8.3%Arm GH: Nivolumab + Ipilimumab
NCT01454102 · Phase 1 · registry result, not featured evidence · combination
—Arm H: Nivolumab + Ipilimumab
NCT01454102 · Phase 1 · registry result, not featured evidence · combination
—Arm I: Nivolumab + Ipilimumab
NCT01454102 · Phase 1 · registry result, not featured evidence · combination
0%Arm IJ: Nivolumab + Ipilimumab
NCT01454102 · Phase 1 · registry result, not featured evidence · combination
—Arm J: Nivolumab + Ipilimumab
NCT01454102 · Phase 1 · registry result, not featured evidence · combination
0%Arm M: Nivolumab
NCT01454102 · Phase 1 · registry result, not featured evidence
12.9%Arm N: Nivolumab + Ipilimumab
NCT01454102 · Phase 1 · registry result, not featured evidence · combination
17.5%Arm O: Nivolumab + Ipilimumab
NCT01454102 · Phase 1 · registry result, not featured evidence · combination
10.5%Arm P: Nivolumab + Ipilimumab
NCT01454102 · Phase 1 · registry result, not featured evidence · combination
7.7%Arm Q: Nivolumab + Ipilimumab
NCT01454102 · Phase 1 · registry result, not featured evidence · combination
44.9%240 mgg
NCT04248829 · Phase 3 · Non-Small Cell Lung Cancer · phase 3
show 6 more results
78.1%Experimental: Arm A (Open-label):
NCT04487080 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
75%Experimental: Arm C (Double-blind)
NCT04487080 · Phase 3 · Non-Small Cell Lung Cancer · phase 3
74.5%Main Study: Arm A: Lazertinib + Am
NCT04988295 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
80.2%Main Study: Arm C: Amivantamab + C
NCT04988295 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
—240 mg
NCT04075396 · Phase 1/2 · registry result, not featured evidence
n/a: no completion milestone320 mg
NCT04075396 · Phase 1/2 · registry result, not featured evidence
Discontinued due to AEs
—f
NCT01351415 · Phase 3 · registry result, not featured evidence · combination
show 42 more results
7.1%
NCT00883779 · Phase 3 · registry result, not featured evidence
—
NCT00257608 · Phase 3 · registry result, not featured evidence · combination
—
NCT00621049 · Phase 2 · registry result, not featured evidence
25%Bevacizumab+Erlotinib
NCT00800202 · Phase 2 · registry result, not featured evidence · combination
10.4%Bevacizumab+Paclitaxel+Carboplatin
NCT00800202 · Phase 2 · registry result, not featured evidence · combination
6.8%
NCT01998919 · Phase 2 · registry result, not featured evidence · combination
—
NCT00701558 · Phase 2 · registry result, not featured evidence · combination
6.3%
NCT00531960 · Phase 2 · registry result, not featured evidence · combination
37.5%
NCT00518011 · Phase 2 · registry result, not featured evidence · combination
—200 mg
NCT02039674 · Phase 1/2 · registry result, not featured evidence · monotherapy
3.3%Part 2 Cohort G+ (Pembro 200 mg+Pe
NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination
7.7%Part 1 Cohort B10 (Pembro 10 mg/kg
NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination
0%Part 1 Cohort C10 (Pembro 10 mg/kg
NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination
0%Part 1 Cohort D1 (Pembro 10 mg/kg+
NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination
0%Part 1 Cohort D2 (Pembro 10 mg/kg+
NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination
—Part 1 Cohort A2 (Pembro 2 mg/kg+P
NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination
0%Part 1 Cohort B2 (Pembro 2mg/kg+Pa
NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination
0%Part 1 Cohort C2 (Pembro 2 mg/kg+P
NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination
16.7%Part 1 Cohort D4 (Pembro 2 mg/kg+I
NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination
8.3%Part 1 Cohort E (Pembro 2 mg/kg+Er
NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination
0%Part 1 Cohort F (Pembro 2 mg/kg+Ge
NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination
3%Part 2 Cohort H (Pembro 2mg/kg+I)
NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination
—Part 1 Cohort A10 (Pembro10mg/kg+P
NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination
—Arm A: Nivolumab + Gemcitabine + C
NCT01454102 · Phase 1 · registry result, not featured evidence · combination
—Arm B: Nivolumab + Pemetrexed + Ci
NCT01454102 · Phase 1 · registry result, not featured evidence · combination
—Arm C10: Nivolumab + Paclitaxel +
NCT01454102 · Phase 1 · registry result, not featured evidence · combination
—Arm C5: Nivolumab + Paclitaxel + C
NCT01454102 · Phase 1 · registry result, not featured evidence · combination
—Arm C: Nivolumab + Paclitaxel + Ca
NCT01454102 · Phase 1 · registry result, not featured evidence · combination
—Arm D: Nivolumab + Bevacizumab Mai
NCT01454102 · Phase 1 · registry result, not featured evidence · combination
—Arm E: Nivolumab + Erlotinib
NCT01454102 · Phase 1 · registry result, not featured evidence · combination
—Arm F: Nivolumab
NCT01454102 · Phase 1 · registry result, not featured evidence
—Arm G: Nivolumab + Ipilimumab
NCT01454102 · Phase 1 · registry result, not featured evidence · combination
—Arm GH: Nivolumab + Ipilimumab
NCT01454102 · Phase 1 · registry result, not featured evidence · combination
—Arm H: Nivolumab + Ipilimumab
NCT01454102 · Phase 1 · registry result, not featured evidence · combination
—Arm I: Nivolumab + Ipilimumab
NCT01454102 · Phase 1 · registry result, not featured evidence · combination
—Arm IJ: Nivolumab + Ipilimumab
NCT01454102 · Phase 1 · registry result, not featured evidence · combination
—Arm J: Nivolumab + Ipilimumab
NCT01454102 · Phase 1 · registry result, not featured evidence · combination
—Arm M: Nivolumab
NCT01454102 · Phase 1 · registry result, not featured evidence
—Arm N: Nivolumab + Ipilimumab
NCT01454102 · Phase 1 · registry result, not featured evidence · combination
—Arm O: Nivolumab + Ipilimumab
NCT01454102 · Phase 1 · registry result, not featured evidence · combination
—Arm P: Nivolumab + Ipilimumab
NCT01454102 · Phase 1 · registry result, not featured evidence · combination
—Arm Q: Nivolumab + Ipilimumab
NCT01454102 · Phase 1 · registry result, not featured evidence · combination
9.7%240 mgg
NCT04248829 · Phase 3 · Non-Small Cell Lung Cancer · phase 3
show 6 more results
—Experimental: Arm A (Open-label):
NCT04487080 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
—Experimental: Arm C (Double-blind)
NCT04487080 · Phase 3 · Non-Small Cell Lung Cancer · phase 3
—Main Study: Arm A: Lazertinib + Am
NCT04988295 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
—Main Study: Arm C: Amivantamab + C
NCT04988295 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
—240 mg
NCT04075396 · Phase 1/2 · registry result, not featured evidence
—320 mg
NCT04075396 · Phase 1/2 · registry result, not featured evidence
Serious AEs
51.9%f
NCT01351415 · Phase 3 · registry result, not featured evidence · combination
show 42 more results
31%
NCT00883779 · Phase 3 · registry result, not featured evidence
23.4%
NCT00257608 · Phase 3 · registry result, not featured evidence · combination
25.5%
NCT00621049 · Phase 2 · registry result, not featured evidence
29.2%Bevacizumab+Erlotinib
NCT00800202 · Phase 2 · registry result, not featured evidence · combination
40.3%Bevacizumab+Paclitaxel+Carboplatin
NCT00800202 · Phase 2 · registry result, not featured evidence · combination
23%
NCT01998919 · Phase 2 · registry result, not featured evidence · combination
10.5%
NCT00701558 · Phase 2 · registry result, not featured evidence · combination
27%
NCT00531960 · Phase 2 · registry result, not featured evidence · combination
75%
NCT00518011 · Phase 2 · registry result, not featured evidence · combination
25%200 mg
NCT02039674 · Phase 1/2 · registry result, not featured evidence · monotherapy
50.8%Part 2 Cohort G+ (Pembro 200 mg+Pe
NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination
61.5%Part 1 Cohort B10 (Pembro 10 mg/kg
NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination
58.3%Part 1 Cohort C10 (Pembro 10 mg/kg
NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination
33.3%Part 1 Cohort D1 (Pembro 10 mg/kg+
NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination
33.3%Part 1 Cohort D2 (Pembro 10 mg/kg+
NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination
53.8%Part 1 Cohort A2 (Pembro 2 mg/kg+P
NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination
72.7%Part 1 Cohort B2 (Pembro 2mg/kg+Pa
NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination
50%Part 1 Cohort C2 (Pembro 2 mg/kg+P
NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination
41.7%Part 1 Cohort D4 (Pembro 2 mg/kg+I
NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination
66.7%Part 1 Cohort E (Pembro 2 mg/kg+Er
NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination
71.4%Part 1 Cohort F (Pembro 2 mg/kg+Ge
NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination
36.4%Part 2 Cohort H (Pembro 2mg/kg+I)
NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination
41.7%Part 1 Cohort A10 (Pembro10mg/kg+P
NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination
33.3%Arm A: Nivolumab + Gemcitabine + C
NCT01454102 · Phase 1 · registry result, not featured evidence · combination
66.7%Arm B: Nivolumab + Pemetrexed + Ci
NCT01454102 · Phase 1 · registry result, not featured evidence · combination
—Arm C10: Nivolumab + Paclitaxel +
NCT01454102 · Phase 1 · registry result, not featured evidence · combination
—Arm C5: Nivolumab + Paclitaxel + C
NCT01454102 · Phase 1 · registry result, not featured evidence · combination
58.6%Arm C: Nivolumab + Paclitaxel + Ca
NCT01454102 · Phase 1 · registry result, not featured evidence · combination
25%Arm D: Nivolumab + Bevacizumab Mai
NCT01454102 · Phase 1 · registry result, not featured evidence · combination
52.4%Arm E: Nivolumab + Erlotinib
NCT01454102 · Phase 1 · registry result, not featured evidence · combination
44.2%Arm F: Nivolumab
NCT01454102 · Phase 1 · registry result, not featured evidence
66.7%Arm G: Nivolumab + Ipilimumab
NCT01454102 · Phase 1 · registry result, not featured evidence · combination
—Arm GH: Nivolumab + Ipilimumab
NCT01454102 · Phase 1 · registry result, not featured evidence · combination
80%Arm H: Nivolumab + Ipilimumab
NCT01454102 · Phase 1 · registry result, not featured evidence · combination
55.6%Arm I: Nivolumab + Ipilimumab
NCT01454102 · Phase 1 · registry result, not featured evidence · combination
—Arm IJ: Nivolumab + Ipilimumab
NCT01454102 · Phase 1 · registry result, not featured evidence · combination
75%Arm J: Nivolumab + Ipilimumab
NCT01454102 · Phase 1 · registry result, not featured evidence · combination
33.3%Arm M: Nivolumab
NCT01454102 · Phase 1 · registry result, not featured evidence
38.7%Arm N: Nivolumab + Ipilimumab
NCT01454102 · Phase 1 · registry result, not featured evidence · combination
52.5%Arm O: Nivolumab + Ipilimumab
NCT01454102 · Phase 1 · registry result, not featured evidence · combination
65.8%Arm P: Nivolumab + Ipilimumab
NCT01454102 · Phase 1 · registry result, not featured evidence · combination
64.1%Arm Q: Nivolumab + Ipilimumab
NCT01454102 · Phase 1 · registry result, not featured evidence · combination
26%240 mgg
NCT04248829 · Phase 3 · Non-Small Cell Lung Cancer · phase 3
show 6 more results
48.7%Experimental: Arm A (Open-label):
NCT04487080 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
35.2%Experimental: Arm C (Double-blind)
NCT04487080 · Phase 3 · Non-Small Cell Lung Cancer · phase 3
52.1%Main Study: Arm A: Lazertinib + Am
NCT04988295 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
32.3%Main Study: Arm C: Amivantamab + C
NCT04988295 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
66.7%240 mg
NCT04075396 · Phase 1/2 · registry result, not featured evidence
46.2%320 mg
NCT04075396 · Phase 1/2 · registry result, not featured evidence
Most frequent reported AEs
f
diarrhoea 37%
nausea 34.6%
decreased appetite 34.2%
NCT01351415 · Phase 3 · registry result, not featured evidence · combination
show 38 more results
rash 62.8% (placebo 32.4%)
neutropenia 50.4% (placebo 49.5%)
nausea 39.8% (placebo 41.4%)
NCT00883779 · Phase 3 · registry result, not featured evidence
rash 55.4% (placebo 18.8%)
diarrhoea 51.1% (placebo 19.6%)
fatigue 34.2% (placebo 24.8%)
NCT00257608 · Phase 3 · registry result, not featured evidence · combination
fatigue 67.3%
nausea 58.2%
diarrhea 47.3%
NCT00621049 · Phase 2 · registry result, not featured evidence
asthenia 62.5%
diarrhoea 62.5%
folliculitis 45.8%
NCT00800202 · Phase 2 · registry result, not featured evidence · combination
asthenia 71.6%
hypertension 52.2%
neutropenia 49.3%
NCT00800202 · Phase 2 · registry result, not featured evidence · combination
rash 64.9% (placebo 40.5%)
nausea 45.9% (placebo 46.8%)
decreased appetite 40.5% (placebo 41.8%)
NCT01998919 · Phase 2 · registry result, not featured evidence · combination
anaemia of malignant disease 36.8%
thrombocytopenia 31.6%
rash 15.8%
NCT00701558 · Phase 2 · registry result, not featured evidence · combination
rash 61.9%
diarrhoea 42.9%
cough 30.2%
NCT00531960 · Phase 2 · registry result, not featured evidence · combination
rash 87.5%
diarrhoea 75%
anorexia 62.5%
NCT00518011 · Phase 2 · registry result, not featured evidence · combination
200 mg
decreased appetite 32.1% (placebo 27.4%)
fatigue 25% (placebo 58.1%)
cough 21.4% (placebo 27.4%)
NCT02039674 · Phase 1/2 · registry result, not featured evidence · monotherapy
nausea 72.9% (placebo 59.7%)
fatigue 69.5% (placebo 58.1%)
constipation 54.2% (placebo 40.3%)
NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination
alopecia 61.5% (placebo 3.2%)
cough 53.8% (placebo 27.4%)
decreased appetite 53.8% (placebo 27.4%)
NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination
fatigue 91.7% (placebo 58.1%)
constipation 58.3% (placebo 40.3%)
anaemia 50% (placebo 58.1%)
NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination
fatigue 100% (placebo 58.1%)
actinic keratosis 33.3% (placebo 1.6%)
back pain 33.3% (placebo 12.9%)
NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination
arthralgia 66.7% (placebo 29%)
chills 66.7% (placebo 4.8%)
cough 66.7% (placebo 27.4%)
NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination
constipation 61.5% (placebo 40.3%)
fatigue 61.5% (placebo 58.1%)
alopecia 53.8% (placebo 3.2%)
NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination
constipation 81.8% (placebo 40.3%)
alopecia 72.7% (placebo 3.2%)
fatigue 72.7% (placebo 58.1%)
NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination
constipation 66.7% (placebo 40.3%)
nausea 58.3% (placebo 59.7%)
fatigue 50% (placebo 58.1%)
NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination
constipation 41.7% (placebo 40.3%)
vomiting 41.7% (placebo 32.3%)
cough 33.3% (placebo 27.4%)
NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination
diarrhoea 66.7% (placebo 30.6%)
fatigue 58.3% (placebo 58.1%)
cough 50% (placebo 27.4%)
NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination
diarrhoea 57.1% (placebo 30.6%)
pruritus 42.9% (placebo 11.3%)
rash 28.6% (placebo 16.1%)
NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination
fatigue 48.5% (placebo 58.1%)
constipation 27.3% (placebo 40.3%)
arthralgia 24.2% (placebo 29%)
NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination
fatigue 66.7% (placebo 58.1%)
alopecia 58.3% (placebo 3.2%)
constipation 58.3% (placebo 40.3%)
NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination
constipation 83.3%
fatigue 83.3%
anaemia 66.7%
NCT01454102 · Phase 1 · registry result, not featured evidence · combination
fatigue 93.3%
nausea 80%
decreased appetite 60%
NCT01454102 · Phase 1 · registry result, not featured evidence · combination
fatigue 79.3%
alopecia 51.7%
constipation 51.7%
NCT01454102 · Phase 1 · registry result, not featured evidence · combination
cough 58.3%
fatigue 50%
dyspnoea 41.7%
NCT01454102 · Phase 1 · registry result, not featured evidence · combination
fatigue 76.2%
rash 61.9%
diarrhoea 47.6%
NCT01454102 · Phase 1 · registry result, not featured evidence · combination
cough 53.8%
fatigue 53.8%
constipation 32.7%
NCT01454102 · Phase 1 · registry result, not featured evidence
decreased appetite 66.7%
diarrhoea 44.4%
fatigue 44.4%
NCT01454102 · Phase 1 · registry result, not featured evidence · combination
fatigue 73.3%
diarrhoea 66.7%
cough 40%
NCT01454102 · Phase 1 · registry result, not featured evidence · combination
fatigue 66.7%
cough 33.3%
decreased appetite 33.3%
NCT01454102 · Phase 1 · registry result, not featured evidence · combination
fatigue 68.8%
decreased appetite 50%
nausea 50%
NCT01454102 · Phase 1 · registry result, not featured evidence · combination
fatigue 58.3%
cough 41.7%
constipation 25%
NCT01454102 · Phase 1 · registry result, not featured evidence
fatigue 51.6%
dyspnoea 41.9%
cough 35.5%
NCT01454102 · Phase 1 · registry result, not featured evidence · combination
rash 35%
diarrhoea 32.5%
fatigue 32.5%
NCT01454102 · Phase 1 · registry result, not featured evidence · combination
pruritus 42.1%
fatigue 36.8%
cough 34.2%
NCT01454102 · Phase 1 · registry result, not featured evidence · combination
fatigue 46.2%
decreased appetite 35.9%
cough 33.3%
NCT01454102 · Phase 1 · registry result, not featured evidence · combination
240 mgg
paraesthesia 39.3%
rash 36.2%
pruritus 26.5%
NCT04248829 · Phase 3 · Non-Small Cell Lung Cancer · phase 3
show 6 more results
paronychia 68.4%
infusion related reaction 62%
rash 61.8%
NCT04487080 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
rash 44.6%
diarrhoea 31.9%
paronychia 28.6%
NCT04487080 · Phase 3 · Non-Small Cell Lung Cancer · phase 3
neutropenia 65.8%
thrombocytopenia 59.3%
infusion related reaction 54%
NCT04988295 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
infusion related reaction 56.9%
neutropenia 56.2%
nausea 44.6%
NCT04988295 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
240 mg
anaemia 46.7%
diarrhoea 46.7%
aspartate aminotransferase increased 26.7%
NCT04075396 · Phase 1/2 · registry result, not featured evidence
320 mg
nausea 61.5%
diarrhoea 53.8%
arthralgia 23.1%
NCT04075396 · Phase 1/2 · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for both studies.
  2. bTreatment context has not been resolved for both arms.
  3. cThe assessment timepoint is not available for both results.
  4. dTrial phases differ: Phase 2 versus Phase 1/2.
  5. eThis study reports multiple eligible drug arms; no representative arm has been reviewed.
  6. fPopulation comparability has not been reviewed for these studies.
  7. gPopulation comparability has not been reviewed for 2 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Erlotinib

Overall Survival 34.5 vs 21.1 placebo months
time to event · months
NCT02039674 · Phase 1/2 · registry result, not featured evidence · combination
show 6 more results
11.86 vs 10.22 Standard of Care months
NCT01351415 · Phase 3 · registry result, not featured evidence · combination
14.4 vs 13.3 placebo months
NCT00257608 · Phase 3 · registry result, not featured evidence · combination
NA vs NA Docetaxel and Carboplatin months
NCT00621049 · Phase 2 · registry result, not featured evidence
17.1 vs 17.47 placebo months*
NCT01998919 · Phase 2 · registry result, not featured evidence · combination · converted to months from 74.1 weeks as posted
16.4 vs NA Bevacizumab + Chemotherapy months
NCT00531960 · Phase 2 · registry result, not featured evidence · combination
9 vs 4.87 Gemcitabine months*
NCT00518011 · Phase 2 · registry result, not featured evidence · combination · converted to months from 39 weeks as posted
PFS2 5.45 vs 3.98 Standard of Care months
time to event · months
PFS 2
NCT01351415 · Phase 3 · registry result, not featured evidence · combination
Overall Survival 0.8% (n=245) vs 0.7% (n=240) Standard of Care @ 26wk
responder rate · % of participants
NCT01351415 · Phase 3 · registry result, not featured evidence · combination
show 2 more results
0.5% (n=245) vs 0.4% (n=240) Standard of Care @ 52wk
NCT01351415 · Phase 3 · registry result, not featured evidence · combination
0.4% (n=245) vs 0.3% (n=240) Standard of Care @ 78wk
NCT01351415 · Phase 3 · registry result, not featured evidence · combination
PFS 22.6% (n=226) vs 6.2% (n=225) placebo
responder rate · % of participants
NCT00883779 · Phase 3 · registry result, not featured evidence
Overall Survival 18.2 vs 15.2 placebo months
time to event · months
Overall participants (n=225,226)
NCT00883779 · Phase 3 · registry result, not featured evidence
Overall Survival 15.9% (n=226) vs 13.3% (n=225) placebo
responder rate · % of participants
Overall participants (n=225,226)
NCT00883779 · Phase 3 · registry result, not featured evidence
Time to Progression 7.9 vs 6.5 placebo months
time to event · months
NCT00883779 · Phase 3 · registry result, not featured evidence
show 1 more result
7.25 vs 5.56 placebo months*
NCT01998919 · Phase 2 · registry result, not featured evidence · combination · converted to months from 31.4 weeks as posted
Symptomatic Progression 66.4% (n=226) vs 72.4% (n=225) placebo
responder rate · % of participants
NCT00883779 · Phase 3 · registry result, not featured evidence
Time to Symptomatic Progression 7.2 vs 6.6 placebo months
time to event · months
NCT00883779 · Phase 3 · registry result, not featured evidence
FACT TOI Deterioration 65.9% (n=226) vs 75.6% (n=225) placebo
ratio to baseline · % of baseline
NCT00883779 · Phase 3 · registry result, not featured evidence
Time to Deterioration FACT TOI 6.3 vs 5.6 placebo months
time to event · months
NCT00883779 · Phase 3 · registry result, not featured evidence
FACT-L Deterioration 70.4% (n=226) vs 79.6% (n=225) placebo
ratio to baseline · % of baseline
NCT00883779 · Phase 3 · registry result, not featured evidence

+ 9 further endpoints in the CSV export.

Lazertinib

Overall Survival 25% (n=196) vs 32.5% (n=197) Gefitnib240 mg
event count · % of participants
Death
NCT04248829 · Phase 3 · Non-Small Cell Lung Cancer · phase 3 · converted to % from 49 Participants as posted
Disease Control 60% (n=15)240 mg
responder rate · % of participants
No placebo or comparator arm
NCT04075396 · Phase 1/2 · registry result, not featured evidence
show 1 more result
53.8% (n=13)320 mg
NCT04075396 · Phase 1/2 · registry result, not featured evidence
Tumor Size -5.37% (n=14)240 mg
percent change · % of baseline
No placebo or comparator arm
NCT04075396 · Phase 1/2 · registry result, not featured evidence
show 1 more result
9.56% (n=12)320 mg
NCT04075396 · Phase 1/2 · registry result, not featured evidence

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Erlotinib's landscape · Lazertinib's landscape